CAR-T Meeting 2022 | Is CAR-T therapy going to replace high-dose chemotherapy with autoSCT in multiple myeloma?
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, talks on the role of high-dose chemotherapy with autologous stem cell transplantation (autoSCT) in the context of chimeric antigen receptor T-cell (CAR-T) therapies in multiple myeloma. CAR T-therapies are undeniably starting to challenge the current standard of care (SOC) due to their high efficacy and low toxicity, and they are currently being investigated in earlier lines of therapy where they are directly compared to chemotherapy and autoSCT. Prof. Einsele explains that CAR-T therapy may also be added to autoSCT as an additional consolidation strategy in high-risk and ultra-high risk disease. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
